Pfizer

Intellect Neurosciences to appeal in European patent proceedings

Wednesday, February 15, 2012 03:30 PM

Intellect Neurosciences, a biopharmaceutical company focused on disease-modifying therapeutic agents for Alzheimer's disease, submitted a statement setting out its grounds for appealing the European Patent Office's (EPO) preliminary decision to revoke the company's Antisenilin (bapineuzumab) patents.

More... »

Delcath appoints Chris Houchins senior VP

Tuesday, February 14, 2012 07:50 AM

Delcath Systems has appointed J. Chris Houchins to the company's clinical development team as senior vice president, clinical and medical affairs.

More... »

Pfizer recalls birth control due to out of order tablets

Monday, February 6, 2012 01:56 PM

Pfizer has voluntarily recalled 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol) tablets and 14 lots of Norgestrel and Ethinyl Estradiol tablets (generic) on the U.S. market—approximately 1 million packs.

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

FDA approves Inlyta to treat advanced kidney cancer

Saturday, January 28, 2012 08:27 AM

The FDA has approved Pfizer’s Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

More... »

Alzheimer's Challenge 2012 seeks new tools to improve Alzheimer's care

Thursday, January 26, 2012 10:47 AM

South San Francisco-based Janssen Alzheimer Immunotherapy, together with Pfizer—its collaborator on the Alzheimer's Immunotherapy Program (AIP)—and the Geoffrey Beene Gives Back Alzheimer's Initiative, have introduced the Alzheimer's Challenge 2012, calling for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer's disease.

More... »

Bayer, Ventana collaborate on test for personalized cancer therapy

Wednesday, January 18, 2012 12:05 PM

Bayer Pharma has collaborated with Ventana Medical Systems, a member of the Roche Group, to develop a molecular companion diagnostic test to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC).

More... »

Roese joins Marken

Thursday, December 22, 2011 11:29 AM

More... »

Russia's cancer drug market to grow to $163 million

Wednesday, December 14, 2011 12:48 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has found that the Russian market for non-small-cell lung cancer therapies will grow 3% annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

More... »

Benedyk joins Amarantus as strategic advisor

Tuesday, December 13, 2011 09:29 AM

Amarantus BioSciences has named Mark J. Benedyk, PhD, strategic advisor effective immediately. In this role, he will support the company with strategy and business development issues.

More... »